Spero Therapeutics, Inc.
No SEC Form 4 filings for $SPRO in the last 30 days.
See all $SPRO insider activity →Spero Therapeutics (NASDAQ:SPRO) reported Q2 2026 revenue of $0 versus $14.2M in Q2 2025, with R&D expense down to $3.4M and G&A up to $6.5M. Net loss was $9.6M. Spero also closed a $105M royalty financing tied to GSK’s Utebzi milestones/royalties, and licensed SP001 (IBI355) from Innovent with $1.1B contingent value; SP001 Phase II in IgG4-RD is expected to start Q2 2027.
Spero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d69249dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update • Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibod
Innovent Biologics licensed IBI355, an Fc-silent anti-CD40L antibody, to Spero Therapeutics for up to $1.1bn. Spero will run a global Phase II study starting Q2 2027, while Innovent keeps commercial rights in Mainland China, Hong Kong, Macau and Taiwan. Innovent also plans a China Phase II for Sjögren’s by early 2027, with upfront, milestones and royalties.
Over the past 7 days, alphai's AI scored 2 news stories mentioning SPRO (Spero Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent SPRO coverage spans corporate actions, mergers & acquisitions and financial news.
Financing reduces near-term funding risk through 2H 2029, while SP001 licensing and planned Phase II timing shape longer-dated valuation expectations.
Multiple catalysts in one filing: FDA approval for Utebzi (via GSK), new Phase 2-ready SP001 program, and non-dilutive royalty financing to fund SP001 into 2029.
Spero expands its immunology pipeline with a defined Phase II launch timeline, but faces execution and funding needs for development.
Spero’s risk profile changes as it transfers ex-China development/commercialization responsibility while retaining upside via milestones/royalties.
The deal provides immediate non-dilutive funding and extends runway, reducing near-term financing risk while preserving upside via retained 35% of future GSK payments.
alphai scores every news story that mentions SPRO with an AI model for sentiment and relevance, and aggregates insider trades from Spero Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Spero Therapeutics (NASDAQ:SPRO) reported Q2 2026 revenue of $0 versus $14.2M in Q2 2025, with R&D expense down to $3.4M and G&A up to $6.5M. Net loss was $9.6M. Spero also closed a $105M royalty financing tied to GSK’s Utebzi milestones/royalties, and licensed SP001 (IBI355) from Innovent with $1.1B contingent value; SP001 Phase II in IgG4-RD is expected to start Q2 2027.
6 min readSpero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d69249dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update • Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibod
6 min readInnovent Biologics licensed IBI355, an Fc-silent anti-CD40L antibody, to Spero Therapeutics for up to $1.1bn. Spero will run a global Phase II study starting Q2 2027, while Innovent keeps commercial rights in Mainland China, Hong Kong, Macau and Taiwan. Innovent also plans a China Phase II for Sjögren’s by early 2027, with upfront, milestones and royalties.
4 min readInnovent Biologics said it signed an exclusive licensing deal with Spero Therapeutics for IBI355, an anti-CD40L antibody for autoimmune diseases. Innovent will get an upfront payment plus development, regulatory and commercial milestones totaling up to about $1.1 billion, and tiered royalties. Spero gets worldwide rights excluding Greater China. IBI355 is in Phase 1 and Phase 2 plans.
2 min readSpero Therapeutics (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing with affiliates of Healthcare Royalty (KKR, HCRx). It funds Phase 2 development of SP001 using a portion of future Utebzi (tebipenem pivoxil) milestones and royalties from GSK. Spero updated cash runway to the second half of 2029.
4 min readSpero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001701108 0001701108 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2
6 min readSpero Therapeutics shares fell about 12% premarket after it announced a $105M licensing deal with HCRx, an affiliate of Healthcare Royalty (KKR). HCRx will receive a share of future milestone and royalty payments tied to Utebzi (tebipenem pivoxil) sales, while Spero plans to fund SP001 Phase 2 and extend cash runway into 2H 2029.
3 min readInnovent Biologics (01801.HK) and Spero Therapeutics (SPRO) announced an exclusive global license for IBI355 (SP001), an anti-CD40L antibody, with Spero holding rights worldwide excluding Greater China. Innovent will receive an upfront payment and milestones totaling about $1.1B plus tiered royalties. Spero plans Phase 2 in IgG4-RD in Q2 2027 and Innovent Phase 2 in China for Sjögren’s by early 2027.
4 min readSpero Therapeutics, Inc. (SPRO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001701108 --12-31 0001701108 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
3 min readBiotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min read
